Obesity Clinical Trial
Official title:
Relation Between Pregnenolone Endocannabinoids in Normal-weight and Obese Men
Measured plasmatic concentration of pregnenolone and endocannabinoid in fasting conditions and over a meal in obese and normal-weight men subjects, to research a dysfunction in the negative feed-back between pregnenolone and CB1 ligand in obese subjects. This dysfunction could participate to the hyperactivity of endocannabinoid system saw in obesity.
Endocannabinoid system is an orexigenic key system, controlling the energy balance. It is
composed of receptors (ex: CB1), of endogenous ligands, the endocannabinoids (ex: anandamide
and 2- arachidonoylglycerol) and of enzymes implied in the synthesis and the degradation of
the endocannabinoids. Researches resulting from our group highlighted anomalies of the
plasmatic concentrations of endocannabinoid, in obese subject compared to normal-weight
subject. Those being higher in obese subject with a flatness of post prandial reduction of
AEA, so maintenance of elevated levels which can facilitate the food catch and create a
metabolic vicious circle. In addition, prestigious research resulting from our collaborators
highlighted in the animal that exposure to tetrahydrocannabinol (THC, ligand exogenic of CB1)
induced the synthesis of pregnenolone (neurosteroid) which, by an autocrine effect on the
CB1, inhibited the effects of the THC. In particular one of the principal behavioural
effects: the food intake.
We want to measure pregnenolone and endocannabinoid concentrations in men blood samples, to
observe if this association exists in fasting conditions and over a meal in normal-weight and
obese subjects. Obese subjects will be recruited during an hospitalization, while normal
subject will be recruited by a poster at Bordeaux university and Haut-Leveque hospital. They
will be included at Haut-Leveque hospital during morning at hospital.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |